TICKERNERD
Menu
CLRBCLRBHealthcare · Biotechnology

CLRB Stock Forecast: Cellectar Biosciences, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$2.58
−0.39% on the day

The 4 Wall Street analysts covering Cellectar Biosciences, Inc. hold a median 12-month price target of $11 — +307.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 25 of 100 as at 22 Aug 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$24.4M
Ticker Nerd rank
25 / 100
Median analyst target
$11
Analysts covering
4
Total return, dividends reinvested
1W
−0.8%
1M
0.0%
YTD
−12.5%
1Y
−42.5%
From 52W high
−58.2%
From 52W low
+15.7%
$2.23
$6.17
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

CLRB stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Cellectar Biosciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
25 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
87
Growth
65
Accruals
50
Volatility
49
Quality
46
Momentum
35
Revisions
31
Issuance
10
Value
7

Size (87): Smaller than most of the companies we track.

Value (7): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

CLRB stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CLRB, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$5.00$10.00$15.00Oct 25Jan 26Apr 26Jul 26CLRBHigh $15Median $11Low $10

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says4 analysts
4 Buy0 Hold0 Sell
Low $10Median $11High $15

The green dot is the last close — the median target sits +307.0% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
15 May 2026Ladenburg ThalmannAssumesBuy$10
10 Mar 2026Maxim GroupUpgradeBuy—
14 May 2025Maxim GroupDowngradeHold—
11 Dec 2024OppenheimerDowngradePerform—
19 Nov 2024OppenheimerMaintainsOutperform—
11 Oct 2024OppenheimerReiteratesOutperform$14
28 Mar 2024OppenheimerReiteratesOutperform—
28 Mar 2024Roth MKMMaintainsBuy—
4 Mar 2024Roth MKMReiteratesBuy—
4 Nov 2022HC Wainwright & Co.MaintainsBuy—
18 July 2022OppenheimerAssumesOutperform$5.50
25 Nov 2020Brookline CapitalInitiatesBuy—
25 Nov 2020H.C. WainwrightInitiatesBuy—
25 Nov 2020Ladenburg ThalmannInitiatesBuy—
25 Nov 2020Maxim GroupInitiatesBuy—
25 Nov 2020OppenheimerInitiatesOutperform—
25 Nov 2020Roth CapitalInitiatesBuy—
1 July 2020OppenheimerInitiatesOutperform—
23 June 2020Maxim GroupInitiatesBuy—
13 Sept 2019Roth CapitalInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CLRB appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

CLRB analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Cellectar Biosciences, Inc. (CLRB) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.3×

Cheaper than 79% of US stocks

Price / sales
—
Price / book
0.7×

Cheaper than 81% of US stocks

EV / EBITDA
0.3×

Cheaper than 59% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−119.6%

Higher than 11% of US stocks

Return on assets
−58.4%

Higher than 6% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

CLRB vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
CLRBCellectar Biosciences, Inc.$24.4M
25
ENLVEnlivex Ltd.$24.7M
31
TVRDTvardi Therapeutics, Inc.$24.8M
28
CVMCEL-SCI Corp.$24.8M
34
JSPRJasper Therapeutics, Inc.$23.8M
38
GRDXGridAI Technologies Corp.$25.3M
38
ATOSAtossa Therapeutics, Inc.$25.3M
23

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Cellectar Biosciences, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest CLRB news & analysis

Cellectar Biosciences, Inc. (CLRB) Discusses Scientific Rationale and Potential of Phospholipid Ether Platform in Targeted Cancer Therapy Transcript

Seeking Alpha · 18 Aug 2026neutral

Cellectar Biosciences discussed the scientific rationale and potential of its phospholipid ether platform in targeted cancer therapy during a presentation, the transcript of which was published by Seeking Alpha.

Why it matters — A CLRB watcher would care because the presentation provides insight into the company's platform technology and its potential application in targeted cancer treatment.

Cellectar Biosciences, Inc. (CLRB) Q2 2026 Earnings Call Transcript

Seeking Alpha · 13 Aug 2026neutral

Seeking Alpha published the transcript of Cellectar Biosciences' Q2 2026 earnings call. The item identifies the company and the source of the transcript release.

Why it matters — A CLRB watcher would care because the earnings call transcript provides direct commentary from company leadership on quarterly results and operations.

Cellectar Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates

GlobeNewsWire · 13 Aug 2026positive

Cellectar Biosciences reported its second quarter 2026 financial results and provided corporate updates. The company initiated site activation for the confirmatory Phase 3 study of Iopofosine I 131, with a New Drug Application submission planned for mid-2027 under the FDA's Accelerated Approval Program.

Why it matters — Progress on the confirmatory Phase 3 study and the planned mid-2027 NDA submission mark an important regulatory milestone for Iopofosine I 131, Cellectar's lead candidate.

Cellectar Biosciences to Report Second Quarter Financial Results and Host a Conference Call on Thursday, August 13, 2026

GlobeNewsWire · 30 July 2026neutral

Cellectar Biosciences announced it will report its second quarter 2026 financial results and provide a corporate update on August 13, 2026, followed by a conference call at 8:30 a.m. ET.

Why it matters — Investors and analysts tracking CLRB will want to hear the company's latest financial performance and corporate update for the quarter ended June 30, 2026.

FAQ

Frequently asked questions about CLRB stock

What is the CLRB stock price forecast for 2026-2027?

The 4 Wall Street analysts covering Cellectar Biosciences, Inc. have a median 12-month price target of $11, with estimates ranging from $10 to $15. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CLRB stock a buy right now?

Of the 4 analysts covering Cellectar Biosciences, Inc., 4 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Cellectar Biosciences, Inc. 25 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CLRB?

As at 22 Aug 2026, Cellectar Biosciences, Inc. ranks 25 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (87 of 100).

Will CLRB stock go up?

No one can know that. What the data says: the median 12-month target from 4 analysts implies +307.0% from the last close, and Ticker Nerd's factor model ranks Cellectar Biosciences, Inc. 25 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CLRB stock forecast for 2030?

No analyst covering Cellectar Biosciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CLRB are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $10 to $15 over the next 12 months.

How has CLRB stock performed over the past year?

Cellectar Biosciences, Inc. returned -42.5% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Cellectar Biosciences, Inc. do?

Cellectar Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative cancer treatments.

What is the latest news on CLRB?

The most recent item we track (Seeking Alpha, 18 Aug 2026): "Cellectar Biosciences, Inc. (CLRB) Discusses Scientific Rationale and Potential of Phospholipid Ether Platform in Targeted Cancer Therapy Transcript". Cellectar Biosciences discussed the scientific rationale and potential of its phospholipid ether platform in targeted cancer therapy during a presentation, the transcript of which was published by Seeking Alpha.

Company

About Cellectar Biosciences, Inc.

Cellectar Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative cancer treatments. The company leverages its proprietary Phospholipid Drug Conjugate (PDC) delivery platform to specifically target and deliver therapeutic agents to cancer cells, aiming to enhance efficacy and reduce off-target effects. Its pipeline includes iopofosine I 131, a radiotherapeutic designed for targeted delivery of iodine-131, currently being investigated in various clinical trials for diseases such as relapsed or refractory Waldenström's macroglobulinemia, multiple myeloma, and pediatric brain tumors. Cellectar's technology platform holds broad potential for developing next-generation cancer-targeting therapies, including chemotherapeutics and radioisotope conjugates. The company's extensive intellectual property portfolio supports exclusivity around its PDC technology and associated programs. Cellectar Biosciences plays a significant role in advancing precision medicine within oncology by focusing on targeted treatment modalities that address unmet medical needs in cancer care.

CEO Mr. James V. Caruso · 11 employees · United States · https://www.cellectar.com